Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
2023 SABCS
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome data of the ADAPTcycle study might influence clinical decisions (Abstract LBO1-05).
The ASCO Post Staff
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Preliminary antitumor activity, which was observed, will be further examined in the phase II trial (ClinicalTrials.gov identifier NCT03939897) (Abstract PS17-06).
The ASCO Post Staff
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).
The ASCO Post Staff
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).
The ASCO Post Staff
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (Abstract GS01-05).
The ASCO Post Staff
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).
